Patents by Inventor Vyvyan Clare Salisbury

Vyvyan Clare Salisbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Determining the sensitivity of a cell to a drug
    Patent number: 9382568
    Abstract: The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agent
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: July 5, 2016
    Assignees: RANDOX LABORATORIES LTD., UNIVERSITY OF THE WEST OF ENGLAND
    Inventors: Vyvyan Clare Salisbury, Habib Mahmoud Alloush, Margaret Ann Smith, Paul John Innocenzi, Mark William Ruddock, Ashley Diane Martin
  • DETERMINING THE SENSITIVITY OF A CELL TO A DRUG
    Publication number: 20110183317
    Abstract: The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agent
    Type: Application
    Filed: August 10, 2009
    Publication date: July 28, 2011
    Applicants: RANDOX LABORATORIES LIMITED, UNIVERSITY OF THE WEST OF ENGLAND
    Inventors: Vyvyan Clare Salisbury, Habib Mahmoud Alloush, Margaret Ann Smith, Paul John Innocenzi, Mark William Ruddock, Ashley Diane Martin